VIDEO: Nivolumab duration limit in kidney cancer may contribute to treatment-free survival
SAN FRANCISCO — In this video, Meredith M. Regan, ScD, discusses a study she presented at the annual ASCO Genitourinary Cancers Symposium that assessed treatment-free survival outcomes among patients with advanced clear cell renal cell carcinoma.
According to the abstract, the phase 2 study included patients with advanced clear cell renal cell carcinoma who were treated with nivolumab (Opdivo, Bristol Myers Squibb) monotherapy for up to 2 years. Eligible patients who experienced disease progression, at any point, or stable disease at 48 weeks received a combination salvage therapy of nivolumab and ipilimumab (Yervoy, Bristol Myers Squibb) for up to 1 year.
Regan, researcher and associate professor of medicine with Dana-Farber Cancer Institute, and colleagues analyzed the data to determine treatment-free survival 3 years after the initiation of therapy.
“This concept of treatment-free survival is this idea that with immunotherapy, treatment may not need to be continuing and we may be able to stop, provide a period for patients without ongoing treatment while their disease is still under control before the need to initiate subsequent therapy,” she said.
Reference:
- Atkins MD, et al. Abstract 604. Presented at: ASCO Genitourinary Cancers Symposium; Feb. 16-18, 2022; San Francisco, California.
Collapse
Healio Interviews
Read more about